Sandbox ap: Difference between revisions
Jump to navigation
Jump to search
Line 154: | Line 154: | ||
| style="background:#F5F5F5;" + |Highest risk for VTE | | style="background:#F5F5F5;" + |Highest risk for VTE | ||
|} | |} | ||
==Pathophysiology of ILD== | |||
{{Family tree/start}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Q01= Insulin-like growth factor (IGF) signalling|Q02=Transforming growth factor (TGF)-β}} | |||
{{Family tree| | | | | | | | | | | | Q01 | | | | | Q02 | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | P02 | | | | P03 | | P04 | | | | | | | | | | | | | | P02=IGF-binding protein 3 (IGFBP-3)|P03=IGF-binding protein 5 (IGFBP-5)|P04=Upregulation of Egr-1 (early growth response protein 1) }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | O02 | | | | | | | | | | | | | | | | | | | | | | | | | O02=Regulates transforming growth factor (TGF)-β }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | A02 | | | | | | | | | | | | | | | | | | | | | A02=Induction of syndecan-2 (SDC2)}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | B01 | | | | | | | | | | | | | | | | | | | | | B01=Activation,proliferation, and migration of fibroblast to the site of injury}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | C01 | | | | | | | | | | | | | | | | | | | C01=Fibroblasts}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | D01 | | | | D02 | | | | | | | | | | | | | | | | D01=Altered PTEN (phosphatase and tensin homologue)/Akt axis|D02=Acquire contractile stress fibres}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | G01 | | | | G02 | | G03 | | | | | | | | | | | | G01= Inactivates Fox (forkhead box) O3a|G02=Protomyofibroblast,composed of cytoplasmic actins|G03=Pleural mesothelial cells (PMCs)}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | H01 | | | | H02 | | H03 | | | | | | | | | | | | H01= Downregulation of cav-1 and Fas expression|H02=De novo expression of α-SMA|H03=TGF-β1-dependent mesothelial–mesenchymal transition}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | I01 | | | | | | I02 | | | | | | | | | | | | | | | | I01=Fibroblast resistant to apoptosis|I02=Myofibroblasts}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | J02 | | J03 | | | | | | | | | | J02=Different ranges of contractions mediated by RhoA/Rho-associated kinase|J03=Changes in intracellular calcium concentrations}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | K02 | | | | | | | | | K04 | K02=Lock step mechanism of cyclic and contractile events}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | L02 | | | | | | L03 | | | | | | | | | K04 | L02=Excess ECM production|L03=Exerting traction force}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | M01 | | | | | | | | | | | | | | | | | M02 | M01=Tissue remodelling}} | |||
{{Family tree| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | |||
{{Family tree| | | | | | | | | | | | | | | N01 | | | | | | | | | | | | | | | | | | N01=Lung Fibrosis}} | |||
{{Family tree/end}} | |||
==References== | ==References== | ||
<references /> | <references /> |
Revision as of 17:56, 2 March 2018
==Classification Gastritis
Gastritis | Etiology | Gasstritis synonyms | |
---|---|---|---|
Non-atrophic |
|
Superficial Diffuse antral gastritis (DAG) Chronic antral gastritis (CAG) Interstitial - follicular Hypersecretory Type B* | |
Atrophic | Autoimmune |
|
Type A* Diffuse corporal Pernicious anemia-associated |
Multifocal atrophic | Helicobacter pylori | Type B*, type AB* | |
Dietary | Environmental | ||
Environmental factors | Metaplastic | ||
Special form | Chemical | Chemical irritation | Reactive |
|
| ||
|
| ||
|
| ||
Radiation | Radiation injury |
Risk assessment table
Scoring criteria for risk assessment* | ||
---|---|---|
Scoring system | Score | Risk |
IMPROVEDD Score[1] | Predicted % VTE risk through 42 days | |
0 | 0.4% | |
1 | 0.6% | |
2 | 0.8% | |
3 | 1.2% | |
4 | 1.6% | |
5-10 | 2.2% | |
Predicted % VTE risk through 77 days | ||
0 | 0.5% | |
1 | 0.7% | |
2 | 1.0% | |
3 | 1.4% | |
4 | 1.9% | |
5-10 | 2.75 | |
IMPROVE score[2] | Predicted % VTE risk through 3 months | |
0 | 0.5% | |
1 | 1.0% | |
2 | 1.7% | |
3 | 3.1% | |
4 | 4% | |
5-8 | 11% | |
Padua Score[3] | < 4 | Low risk for VTE |
≥ 4 | High risk for VTE | |
Caprini score[4] | 0-1 | Low risk of VTE |
2 | Moderate of VTE | |
3-4 | High risk of VTE | |
≥ 5 | Highest risk for VTE |
Pathophysiology of ILD
{{{ Q01 }}} | {{{ Q02 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IGF-binding protein 3 (IGFBP-3) | IGF-binding protein 5 (IGFBP-5) | Upregulation of Egr-1 (early growth response protein 1) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regulates transforming growth factor (TGF)-β | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Induction of syndecan-2 (SDC2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Activation,proliferation, and migration of fibroblast to the site of injury | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fibroblasts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Altered PTEN (phosphatase and tensin homologue)/Akt axis | Acquire contractile stress fibres | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inactivates Fox (forkhead box) O3a | Protomyofibroblast,composed of cytoplasmic actins | Pleural mesothelial cells (PMCs) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Downregulation of cav-1 and Fas expression | De novo expression of α-SMA | TGF-β1-dependent mesothelial–mesenchymal transition | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fibroblast resistant to apoptosis | Myofibroblasts | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Different ranges of contractions mediated by RhoA/Rho-associated kinase | Changes in intracellular calcium concentrations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lock step mechanism of cyclic and contractile events | {{{ K04 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Excess ECM production | Exerting traction force | {{{ K04 }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Tissue remodelling | {{{ M02 }}} | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lung Fibrosis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ . doi:10.1055/s-0037-160392910.1055/s-0037-1603929. Missing or empty
|title=
(help) - ↑ Spyropoulos AC, Anderson FA, Fitzgerald G, Decousus H, Pini M, Chong BH; et al. (2011). "Predictive and associative models to identify hospitalized medical patients at risk for VTE". Chest. 140 (3): 706–14. doi:10.1378/chest.10-1944. PMID 21436241.
- ↑ Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M; et al. (2010). "A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score". J Thromb Haemost. 8 (11): 2450–7. doi:10.1111/j.1538-7836.2010.04044.x. PMID 20738765.
- ↑ Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F (1991). "Clinical assessment of venous thromboembolic risk in surgical patients". Semin Thromb Hemost. 17 Suppl 3: 304–12. PMID 1754886.